Umoja wa Ulaya - Kislovakia - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - rituximab - lymphoma, non-hodgkin; microscopic polyangiitis; leukemia, lymphocytic, chronic, b-cell; wegener granulomatosis - antineoplastické činidlá - rituzena je indikovaný u dospelých na nasledujúcich označení:non-hodgkin je lymfóm (nhl)rituzena je indikovaný na liečbu doteraz neliečených pacientov s fáza iii iv follicular lymfóm v kombinácii s chemoterapiou. rituzena monotherapy je indikovaný na liečbu pacientov s fáza iii iv follicular lymfóm, ktorí sú odolné voči chemoterapii alebo sú v ich druhom a ďalších relapsu po chemoterapii. rituzena je indikovaný na liečbu pacientov s cd20 pozitívne plošných veľké b bunky non hodgkin je lymfóm v kombinácii s chop (cyklofosfamidom, doxorubicin, vincristine, prednisolone) chemoterapia. chronic lymphocytic leukémia (cll)rituzena v kombinácii s chemoterapiou je indikovaný na liečbu pacientov s predtým neliečených a relapsed/žiaruvzdorné cll. len obmedzené údaje o účinnosti a bezpečnosti pacientov v minulosti liečených monoklonálne protilátky, vrátane rituzenaor pacientov žiaruvzdorné na predchádzajúcu rituzena plus chemoterapia. granulomatosis s polyangiitis a mikroskopické polyangiitisrituzena, v kombinácii s glucocorticoids, je indikovaný na indukciu odpustenie u dospelých pacientov s ťažkou, aktívne granulomatosis s polyangiitis (wegener) (gpa) a mikroskopické polyangiitis (mpa).

Umoja wa Ulaya - Kislovakia - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - viacnásobný myelóm - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Umoja wa Ulaya - Kislovakia - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymfóm, mantle-cell - antineoplastické činidlá - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Umoja wa Ulaya - Kislovakia - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastické činidlá - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Umoja wa Ulaya - Kislovakia - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastické činidlá - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Umoja wa Ulaya - Kislovakia - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastické činidlá - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Umoja wa Ulaya - Kislovakia - EMA (European Medicines Agency)

gentium s.r.l. - defibrotidu - hepatálna veno-okluzívna choroba - antitrombotické činidlá - defitelio je indikovaný na liečbu závažného ochorenia pečene venookluzívna (vod) tiež známy ako sínusová obštrukčná syndróm (sos) v krvotvorných kmeňových buniek-transplantácie (hsct) terapia. to je indikovaný u dospelých a dospievajúcich, deti a dojčatá od 1 mesiaca veku.

Umoja wa Ulaya - Kislovakia - EMA (European Medicines Agency)

lipomed gmbh - cladribine - leukémia, chlpatá bunka - antineoplastické činidlá - liek litak je indikovaný na liečbu leukémie vlasatých buniek.

Umoja wa Ulaya - Kislovakia - EMA (European Medicines Agency)

adienne s.r.l. s.u. - thiotepa - transplantácia hematopoetických kmeňových buniek - antineoplastické činidlá - v kombinácii s inými chemoterapia liekov:s alebo bez celkovej telesnej ožiareniu (tbi), ako je klimatizácia liečba pred allogeneic alebo autológne hematopoetickú predok buniek transplantácia (hpct) v hematologické ochorenia u dospelých a pediatrických pacientov, keď vysoké dávky chemoterapie s hpct podpory je vhodné pre liečbu solídne nádory u dospelých a pediatrických pacientov. navrhuje sa, aby tepadina musí byť predpísané lekármi zažil v klimatizácia liečba pred hematopoetickú predok bunky transplantáciu.

Slovakia - Kislovakia - ŠÚKL (Štátny ústav pre kontrolu liečiv)

g.l. pharma gmbh, rakúsko - topiramát - 21 - antiepileptica, anticonvulsiva